Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

Technology appraisal guidance
Reference number: TA316
Published: 23 July 2014

British Uro-oncology Group: response to scrutiny letter

British Uro-oncology Group: response to scrutiny letter

British Uro-oncology Group: response to scrutiny letter
23 July 2014
(213.97 Kb 2 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 July 2014